Answers are grounded in this paper and cite their sources.
Case report reveals sustained viral suppression in an HIV patient 18 months after stopping long-acting cabotegravir/rilpivirine despite low oral adherence, highlighting prolonged tail activity.
Long-acting cabotegravir/rilpivirine offers a low incidence of virologic failure. However, drug resistance can develop after discontinuation without an effective replacement regimen due to its long pharmacokinetic tail. We present a case of sustained virologic suppression 18 months after discontinuation of long-acting cabotegravir/rilpivirine despite inadequate adherence to oral antiretroviral therapy.
No takes yet. Share an insight, caveat, or question.
Sunagawa et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: